Neurizon Therapeutics Limited (ASX:NUZ), Alterity Therapeutics Limited (ASX:ATH) and Actinogen Medical Limited (ASX:ACW) are developing treatments for neurological diseases with substantial unmet medical need. Neurizon is targeting amyotrophic lateral sclerosis, Alterity is developing a therapy for multiple system atrophy, while Actinogen is progressing Xanamem for Alzheimer’s disease and other neurological conditions.

All three remain development-stage businesses, making cash resources, research spending and access to additional funding central to their financial profiles. Their near-term outlooks are also closely linked to clinical progress rather than commercial revenue.

2026 Neuro-Biotech Context

Neurological Drug Development remains a high-risk area because large and expensive studies are often required to demonstrate meaningful clinical benefit. Smaller developers therefore depend heavily on Equity funding, research incentives, partnerships and other sources of capital.

Clinical milestones can materially change development plans, but positive regulatory feedback or early-stage data do not guarantee eventual approval. Funding discipline remains particularly important for companies advancing programmes toward larger pivotal trials.

Neurizon Therapeutics Limited (ASX:NUZ)

Company Profile

Neurizon is a clinical-stage biotechnology company developing NUZ-001 for amyotrophic lateral sclerosis, also known as ALS or motor neurone disease.

The programme is being evaluated through the HEALEY ALS Platform Trial, which allows several potential treatments to be studied through a shared clinical infrastructure.

Financial Position

Neurizon remains pre-revenue, with income primarily linked to grants and Research and Development incentives rather than product sales.

For the half-year ended 31 December 2025, the company reported a net loss of AUD 5.5 million and cash of AUD 7.9 million.

The company subsequently accessed a broader funding package comprising equity and convertible financing and has stated that it remains funded through the expected topline clinical readout and trial completion.

Outlook and Risks

Neurizon’s financial outlook is closely linked to continued funding of its ALS development programme.

The company expects clinical data from the HEALEY programme during 2027. Until then, Cash Management and financing arrangements remain important.

Clinical risk remains significant because the company is largely dependent on a single development asset, while future financing could result in further dilution.

Alterity Therapeutics Limited (ASX:ATH)

Company Profile

Alterity Therapeutics is developing ATH434, an oral therapy targeting multiple system atrophy, a progressive neurological disorder with limited treatment options.

The company has completed Phase 2 development and is preparing for a pivotal Phase 3 programme following regulatory discussions.

FY2026 Financial Performance

For the year ended 30 June 2026, Alterity reported an operating loss of approximately AUD 23.4 million.

Operating cash outflow was around AUD 22.5 million as the company increased spending on clinical development and preparations for the next trial stage.

Cash stood at AUD 37.3 million at the end of the June quarter.

Alterity also received approximately AUD 3.98 million through the research and development tax incentive shortly after the end of the financial year.

The company is evaluating funding and Partnership Options to support the next stage of ATH434 development.

Outlook and Risks

Alterity is preparing for a Phase 3 programme involving approximately 200 patients.

The main financial issue is the cost of running a late-stage international clinical trial relative to current cash resources.

Additional funding or a strategic partnership may therefore be required. The Business also remains concentrated around ATH434, making the next clinical stage particularly important.

Actinogen Medical Limited (ASX:ACW)

Company Profile

Actinogen Medical is developing Xanamem, also known as emestedastat, for neurological conditions including Alzheimer’s disease.

Its lead programme is XanaMIA, a late-stage clinical study assessing the treatment in patients with mild-to-moderate Alzheimer’s disease.

Financial Position

Actinogen remains pre-revenue. For the half-year ended 31 December 2025, the company reported total income of AUD 2.11 million, including research and development incentive income and interest.

Net loss after tax was AUD 11.35 million.

Cash stood at AUD 16.7 million at 30 June 2026.

During September 2026, Actinogen secured approximately AUD 4.77 million through an Underwriting arrangement covering outstanding options. Management indicated that the additional funding extends the company's expected cash runway into late 2027 or early 2028.

Outlook and Risks

The key near-term focus is the XanaMIA clinical programme, with topline results expected in November 2026.

A positive result could support further pivotal development, which would also increase future funding requirements.

The company therefore faces both clinical and Capital risk. Its financial outlook will depend significantly on the trial result and the scale of any subsequent development programme.

Risks to Watch

Neurizon remains dependent on clinical success and continued access to development funding, with limited commercial Diversification outside its lead programme.

Alterity has the largest reported cash position of the three but is approaching a more expensive Phase 3 stage that could require additional financing.

Actinogen has extended its cash runway, although a successful XanaMIA result would likely lead to further Investment in late-stage development.

Across all three companies, clinical outcomes remain the main determinant of future funding needs and development strategy.

Outlook Through the Rest of 2026

Neurizon remains focused on progressing its ALS programme toward a 2027 clinical readout while managing the funding required to complete development.

Alterity enters its next phase with AUD 37.3 million of reported cash and preparations underway for Phase 3 development of ATH434.

Actinogen enters the final months of 2026 with AUD 16.7 million of June-end cash plus additional funding secured through option underwriting, while the November XanaMIA readout remains the most important near-term development.

The three companies therefore represent different stages of neurological drug development, but their financial priorities remain similar: preserve funding, progress clinical programmes and prepare for potentially larger future trials.